[1] |
熊海林,刘洵祺,孙爱华,等.多西紫杉醇联合希罗达或替吉奥一线治疗晚期胃癌的临床观察[J].现代肿瘤医学,2013,21(3):581-584.
|
[2] |
Aroldi F,Ogliosi C,Zaniboni A.Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer:poliambulanza experience[J].Recenti Prog Med,2016,107(4):193-198.
|
[3] |
汝童,刘铁夫.胃癌诊断的研究进展[J].医学综述,2014,20 (24):4475-4477.
|
[4] |
丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.
|
[5] |
Han FH,Zhou SN,Li HM,et al.Vascularizing lymph node dissection for advanced gastric cancer:a single-institution experience[J].World J Gastroenterol,2016,22(14):3813-3820.
|
[6] |
王强,张熔熔,于志琴,等.Xelox方案序贯希罗达单药维持治疗晚期胃癌的临床观察[J].中国煤炭工业医学杂志,2014,17(7):1048-1050.
|
[7] |
Takahashi A,Kamio Y,Ozawa K,et al.Total gastrectomy for advanced gastric cancer after coronary artery bypass grafting using the right gastroepiploic artery:report of a case [J].Kyobu Geka,2016,69(2):156-159.
|
[8] |
欧阳一.奥沙利铂联合希罗达治疗晚期胃癌临床观察[J].中医临床研究,2014,6(21):131-132.
|
[9] |
Kosaka T,Akiyama H,Makino H,et al.Impact of neoadjuvant chemotherapy among patients with pancreatic fistula after gastrectomy for advanced gastric cancer[J].Anticancer Res,2016,36(4):1773-1777.
|
[10] |
王会忠.不同化疗方案在晚期胃癌治疗中的临床效果比较[J].实用癌症杂志,2014,29(2):183-184.
|
[11] |
Mokmeli S,Tehrani GA,Zamiri RE,et al.Investigating the frequency of the ERCC1 Gene C8092A polymorphism in iranian patients with advanced gastric cancer receiving platinum-based chemotherapy[J].Asian Pac JCancer Prev,2016,17(3):1369-1372.
|
[12] |
林菜梅,罗泽民,罗燕娜,等.顺铂联合希罗达方案与奥沙利铂联合希罗达方案治疗晚期胃癌的疗效分析[J].黑龙江医学,2015,39(4):431-432.
|
[13] |
乌云高娃,李文新,苏日拉,等.多西他赛联合奥沙利铂、卡培他滨一线治疗晚期胃癌临床观察[J].现代肿瘤医学,2014,22(12):2936-2937.
|
[14] |
郭良苏.晚期胃癌腹腔灌注化疗70例临床分析[J].转化医学电子杂志,2015,2(6):64-66.
|
[15] |
韩毓,曲兴龙,柴宇啸,等.多西他赛联合替吉奥新辅助化疗治疗进展期胃癌的疗效和安全性[J].肿瘤,2013,33 (8):734-738.
|